tetano
Editor, Senior Moderator
Diagn Microbiol Infect Dis. 2012 Oct 18. pii: S0732-8893(12)00383-5. doi: 10.1016/j.diagmicrobio.2012.09.005. [Epub ahead of print]
Evaluation of the specificity and sensitivity of a potential rapid influenza screening system.
Perez LE, Merrill GA, Delorenzo RA, Schoenfeld TW, Vats A, Moser MJ.
Source
Department of Clinical Investigation, Brooke Army Medical Center, Ft. Sam Houston, TX 78234-6315, USA. Electronic address: Luis.Perez2@amedd.army.mil.
Abstract
Influenza remains a serious worldwide health threat with numerous deaths attributed to influenza-related complications. It is likely that transmission of influenza and both the morbidity and mortality of influenza could be reduced if inexpensive but reliable influenza screening assays were more available to the general public or local medical treatment facilities. This report provides the initial evaluation of a pilot system designed by Lucigen Corp. (Middleton, WI, USA) as a potential rapid near point-of-care screening system for influenza A and influenza B. The evaluation of specificity and sensitivity was conducted on stored nasal swab samples collected from emergency department patients presenting with influenza-like symptoms at a large military academic hospital and on de-identified nasal swabs and isolated RNA from a local epidemiology laboratory. The gold standard for assessment of specificity and sensitivity was the Luminex? Respiratory Viral Panel.
Published by Elsevier Inc.
PMID:
23083638
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23083638
Evaluation of the specificity and sensitivity of a potential rapid influenza screening system.
Perez LE, Merrill GA, Delorenzo RA, Schoenfeld TW, Vats A, Moser MJ.
Source
Department of Clinical Investigation, Brooke Army Medical Center, Ft. Sam Houston, TX 78234-6315, USA. Electronic address: Luis.Perez2@amedd.army.mil.
Abstract
Influenza remains a serious worldwide health threat with numerous deaths attributed to influenza-related complications. It is likely that transmission of influenza and both the morbidity and mortality of influenza could be reduced if inexpensive but reliable influenza screening assays were more available to the general public or local medical treatment facilities. This report provides the initial evaluation of a pilot system designed by Lucigen Corp. (Middleton, WI, USA) as a potential rapid near point-of-care screening system for influenza A and influenza B. The evaluation of specificity and sensitivity was conducted on stored nasal swab samples collected from emergency department patients presenting with influenza-like symptoms at a large military academic hospital and on de-identified nasal swabs and isolated RNA from a local epidemiology laboratory. The gold standard for assessment of specificity and sensitivity was the Luminex? Respiratory Viral Panel.
Published by Elsevier Inc.
PMID:
23083638
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23083638